Share-based Payment Arrangement, Expense of SUTRO BIOPHARMA, INC. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
SUTRO BIOPHARMA, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • SUTRO BIOPHARMA, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,552,000, a 76% decline year-over-year.
  • SUTRO BIOPHARMA, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $18,268,000, a 27% decline year-over-year.
  • SUTRO BIOPHARMA, INC. annual Share-based Payment Arrangement, Expense for 2024 was $24,687,000, a 0.89% decline from 2023.
  • SUTRO BIOPHARMA, INC. annual Share-based Payment Arrangement, Expense for 2023 was $24,908,000, a 5.3% decline from 2022.
  • SUTRO BIOPHARMA, INC. annual Share-based Payment Arrangement, Expense for 2022 was $26,304,000, a 13% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

SUTRO BIOPHARMA, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $18,268,000 $1,552,000 -$4,993,000 -76% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $23,261,000 $5,263,000 -$896,000 -15% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $24,157,000 $5,538,000 -$530,000 -8.7% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $24,687,000 $5,915,000 -$308,000 -4.9% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $24,995,000 $6,545,000 +$542,000 +9% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $24,453,000 $6,159,000 -$502,000 -7.5% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $24,955,000 $6,068,000 +$47,000 +0.78% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $24,908,000 $6,223,000 +$371,000 +6.3% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $24,537,000 $6,003,000 -$779,000 -11% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $25,316,000 $6,661,000 -$35,000 -0.52% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $25,351,000 $6,021,000 -$953,000 -14% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $26,304,000 $5,852,000 -$1,035,000 -15% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2025 2024 FY
Q3 2022 $27,339,000 $6,782,000 +$287,000 +4.4% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $27,052,000 $6,696,000 +$789,000 +13% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $26,263,000 $6,974,000 +$3,022,000 +76% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $23,241,000 $6,887,000 +$3,800,000 +123% 01 Oct 2021 31 Dec 2021 10-K 25 Mar 2024 2023 FY
Q3 2021 $19,441,000 $6,495,000 +$3,383,000 +109% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $16,058,000 $5,907,000 +$2,896,000 +96% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $13,162,000 $3,952,000 +$1,245,000 +46% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $11,917,000 $3,087,000 +$404,000 +15% 01 Oct 2020 31 Dec 2020 10-K 30 Mar 2023 2022 FY
Q3 2020 $11,513,000 $3,112,000 +$232,000 +8.1% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $11,281,000 $3,011,000 +$548,000 +22% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $10,733,000 $2,707,000 +$421,000 +18% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $10,312,000 $2,683,000 -$188,198 -6.6% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $10,500,198 $2,880,000 +$2,879,679 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $7,620,519 $2,463,000 +$2,462,768 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $5,157,751 $2,286,000 +$2,285,751 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $2,872,000 $2,871,198 01 Oct 2018 31 Dec 2018 10-K 18 Mar 2021 2020 FY
Q3 2018 $321* -$272 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $232* 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 $249* 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
Q3 2017 $593* 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3

SUTRO BIOPHARMA, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $24,687,000 -$221,000 -0.89% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $24,908,000 -$1,396,000 -5.3% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $26,304,000 +$3,063,000 +13% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2025 2024 FY
2021 $23,241,000 +$11,324,000 +95% 01 Jan 2021 31 Dec 2021 10-K 25 Mar 2024 2023 FY
2020 $11,917,000 +$1,605,000 +16% 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2023 2022 FY
2019 $10,312,000 +$7,440,000 +259% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $2,872,000 +$1,481,000 +106% 01 Jan 2018 31 Dec 2018 10-K 18 Mar 2021 2020 FY
2017 $1,391,000 +$423,000 +44% 01 Jan 2017 31 Dec 2017 10-K 16 Mar 2020 2019 FY
2016 $968,000 01 Jan 2016 31 Dec 2016 10-K 01 Apr 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.